A rare young case of Embryonic rhabdomyosarcoma of the prostate with multiple metastases throughout the body: A case report

A rare young case of Embryonic rhabdomyosarcoma of the prostate with multiple metastases throughout the body: A case report | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Case Report A rare young case of Embryonic rhabdomyosarcoma of the prostate with multiple metastases throughout the body: A case report Kai Wang, Yong Ou, Ting-yu Jia, Zhong Zheng, Hua-kang Wang, Ming-xian Chen, and 4 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-4835590/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Prostate cancer is the second most commonly diagnosed cancer and the sixth leading cause of cancer death among men worldwide, with an estimated 1 276 000 new cancer cases and 359 000 deaths in 2018[ 1 ]. The median age at diagnosis is 66 year, and 69% of deaths occur in men aged 75 yr[ 2 ]. As the morbidity and mortality rates rise sharply with age, the burden of prostate cancer will increase with the exponential aging of the population. The pathological type of prostate cancer is mainly adenocarcinoma (98.1%), and other types are relatively rare. Other pathological types of prostate cancer include iprostate duct (endometrioid) ademocarcinoma, small cell carcinoma, smucinous adenocarcinoma, signet ring cell carcinoma, transitional cell carcinoma, Sarcomatoid carcinoma, squamous cell carcinoma, lymphoepithelioid carcinoma, adenoid cystic carcinoma, etc. Rhabdomyosarcoma (RMS) is a soft tissue sarcoma that histologically resembles embryonic skeletal muscle. It can occur anywhere in the body, including tissues devoid of skeletal muscles. The cell of origin of RMS remains unknown, however, recent evidence suggests that RMS can originate from aberrant development of non-myogenic cells [ 3 ]. Rhabdomyosarcoma is a common malignant tumor in children. In fact, it accounts for more than 50% of all soft tissue sarcomas in children [ 4 ]. However, rhabdomyosarcoma is a rare adult malignant tumor, and it accounts for only 3% of all soft tissue sarcomas [ 5 ]. Rhabdomyosarcoma is very rare in prostate tumors. Embryonic rhabdomyosarcoma Prostate Urology Figures Figure 1 Case Report A 36-year-old man visited the outpatient clinic for one month due to dysuria, weak urine flow, and increased nocturia. He denied fever and other constitutional symptoms. He did not observe blood in urine and semen. No history of urinary tract infection, nephrolithiasis, malignancy or neurological disease was reported. The outpatient clinic arranged routine urine examinations and urinary tract color Doppler ultrasound examinations for patients. Due to the severe dysuria symptoms, the patient was treated with catheterization. The patient is admitted to the hospital on the advice of a doctor, after admission, a magnetic resonance imaging(MRI) scan of the pelvic cavity showed that the prostate was significantly enlarged(Prostate volume: 7.0*6.3*6.2cm), the shape of the prostate was irregular and its density was uneven (Fig. 1 a, b). Laboratory analysis revealed white blood cell count 11.08 × 10 9 /l, hemoglobin 12.8 g/dl, platelet count 257 × 10 9 /l. Urinalysis, urine culture, electrolytes including fasting and post prandial blood sugar, serum calcium and alkaline phosphatase were unremarkable. Prostate specific antigen (tPSA) level was 0.45 ng/ml (normal PSA 0–4 ng/ml) and free prostate specific antigen(fPSA) level was 0.03 ng/ml. A transrectal ultrasound guided biopsy of the prostate revealed prostate cancer. Due to the difficulty of pathological diagnosis, the patient’s pathological specimens were stained by immunohistochemistry. Immunohistochemistry confirmed the diagnosis of Embryonic rhabdomyosarcoma of the prostate (Fig. 1 c, d). Ki 67 index was elevated to 60%. Sections were negative for LCA, GATA-3, P63, CK-H, PSA, P504S, AR, CD30, SALL, CK, CD10, CyclinD1, NSE and S-100. Sections were positive for FLI-I, ERG, Syn, Myogenin, CD99, CD56, Vim and Des. The patient refused genetic testing. The patient underwent a PET-CT scan that showed multiple metastases throughout the patient's body. Discussion Men under 40 years of age reported in the literature on prostate cancer are very rare, with an incidence of 0.8–1.1% [ 6 – 7 ]. The vast majority of prostate cancers are accompanied by elevated prostate-specific antigen (PSA) levels [ 8 ]. PSA level is lower in these patients due to poorly differentiated adenocarcinoma of prostate. So in poorly differentiated carcinoma, PSA level is not indicative of prostate cancer. Compared with elderly patients, men with early-onset prostate cancer are more likely to have more genetic variants, which is related to an increased risk of prostate cancer. In addition, most patients with early-onset prostate cancer are diagnosed as moderately-poorly differentiated diseases, so the management of patients with early-onset prostate cancer presents unique clinical challenges [ 9 ]. First-line therapy for prostate cancer includes androgen deprivation therapy (ADT), depriving both the normal and malignant prostate cells of androgens required for proliferation and survival. However, embryonic rhabdomyosarcoma is an androgen-independent tumor. Therefore, the treatment of this patient with ADT is ineffective. Embryonal rhabdomyosarcoma (ERMS) is a malignant soft tissue tumor with morphologic and immunophenotypic features of embryonic skeletal muscle [ 10 ]. The most common sites are cervical-cephalic and genitourinary and have worse prognosis [ 11 – 12 ]. Treatment options for embryonic rhabdomyosarcoma include chemotherapy, radiotherapy, Surgery, Immunotherapy [ 13 ]. The patient has tumor metastases in multiple organs throughout the body, and the curative effect of radical surgery on the patient’s prostate is also limited. For the patient, he should choose chemotherapy, radiotherapy and other treatment options. Abbreviations RMS Rhabdomyosarcoma MRI magnetic resonance imaging fPSA free prostate specific antigen ADT androgen deprivation therapy ERMS Embryonal rhabdomyosarcoma Declarations Acknowledgements None. Author Contributions Conception and design: KW and ZC. Acquisition of data: YO, ZZ, YJ, MC, HY, YH, ZS, HW, HH and HC. Manuscript editing: KW and FC. All authors contributed to the article and approved the submitted version. Funding NONE Ethics approval and consent to participate Written informed consent to participate was obtained from the patient of this case report. A copy of the written consent is available for review by the Editor of this journal. Consent for publication Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal. Conflicts of Interest All authors declare that there are no conflicts of interest. Date Availability Statement The raw data supporting the conclusions of this article will be made available by the authors without undue reservation. Please contact the author Kai Wang (email: [email protected] ). References Culp MaryBeth B, Soerjomataram Isabelle, Efstathiou Jason A, et al. Recent Global Patterns in Prostate Cancer Incidence and Mortality Rates. [J] Eur Urol. 2020;77:38–52. Gilles DJ-PA, Silke G, et al. Management of Prostate Cancer in Elderly Patients: Recommendations of a Task Force of the International Society of Geriatric Oncology. [J] Eur Urol. 2017;72:521–31. Drummond CJ, Hanna JA, Garcia MR, et al. Hedgehog Pathway Drives Fusion-Negative Rhabdomyosarcoma Initiated From Non-myogenic Endothelial Progenitors. Cancer Cell. 2018;33:108–24. e5. Pastore G, Peris-Bonet R, Carli M, et al. Childhood soft tissue sarcomas incidence and survival in European children (1978–1997): report from the Automated Childhood Cancer Information System project. Eur J Cancer. 2006;42:2136–49. Weiss SW, Goldblum J, Weiss SW, et al. editors. Enzinger and Weiss’s Soft Tissue Tumors. 4th ed. St. Louis: CV Mosby; 2001. pp. 785–835. Roberts JT, Essenhigh DM. Adenocarcinoma of prostate in 40-year-old body-builder. [J] Lancet. 1986;2:742. Ruska KM, Partin AW, Epstein JI, et al. Adenocarcinoma of the prostate in men younger than 40 years of age: diagnosis and treatment with emphasis on radical prostatectomy findings. [J] Urol. 1999;53:1179–83. Cazanave Mora Juliette M et al. Del Valle García Ruben, Pérez López Lilian. Measurement of total and free prostate specific antigen (PSA) in human serum samples using an ultra-microanalytical system.[J].J Pharm Biomed Anal, 2021, 208: 114470. Lange EM, Salinas CA, Zuhlke KA, Ray AM, Wang Y, Lu Y, Ho LA, Luo J, Cooney KA. Early onset prostate cancer has a significant genetic component. Prostate. 2012;72:147–56. Maniraj J, Ann MR, Munchel Ashley Taylor-King. Embryonal Rhabdomyosarcoma with Posttherapy Cytodifferentiation and Aggressive Clinical Course. [J]. Case Rep Pathol, 2021, 2021: 1800854. Pappo AS, Shapiro DN, Crist WM, et al. Biology and therapy of pediatric rhabdomyosarcoma. [J]. J Clin Oncol. 1995;13:2123–39. Leaphart Cynthia,Rodeberg David,Pediatric surgical oncology: management of rhabdomyosarcoma[. J] Surg Oncol, 2007, 16: 173–85. Catalina R-M, Goldberg John M, Coronado Munoz Alvaro J, et al. Rhabdomyosarcoma in adults: new perspectives on therapy. [J]. Curr Treat Options Oncol. 2015;16:27. Additional Declarations No competing interests reported. Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-4835590","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Case Report","associatedPublications":[],"authors":[{"id":346561446,"identity":"72460879-3aba-44fe-85d4-d8f19ad2de8f","order_by":0,"name":"Kai Wang","email":"","orcid":"","institution":"Xichang People's Hospital","correspondingAuthor":false,"prefix":"","firstName":"Kai","middleName":"","lastName":"Wang","suffix":""},{"id":346561447,"identity":"4db82b70-b5c1-4c85-97b5-b0a67a3fa91a","order_by":1,"name":"Yong Ou","email":"","orcid":"","institution":"Xichang People's Hospital","correspondingAuthor":false,"prefix":"","firstName":"Yong","middleName":"","lastName":"Ou","suffix":""},{"id":346561448,"identity":"b63f999b-65a5-4705-a9eb-f990b9644f7c","order_by":2,"name":"Ting-yu Jia","email":"","orcid":"","institution":"Xichang People's Hospital","correspondingAuthor":false,"prefix":"","firstName":"Ting-yu","middleName":"","lastName":"Jia","suffix":""},{"id":346561449,"identity":"1fc202b9-7b92-4467-b7e2-e3cea23b98b8","order_by":3,"name":"Zhong Zheng","email":"","orcid":"","institution":"Xichang People's Hospital","correspondingAuthor":false,"prefix":"","firstName":"Zhong","middleName":"","lastName":"Zheng","suffix":""},{"id":346561450,"identity":"e2ccf64f-f593-4171-b65f-02dfd8754be3","order_by":4,"name":"Hua-kang Wang","email":"","orcid":"","institution":"Xichang People's Hospital","correspondingAuthor":false,"prefix":"","firstName":"Hua-kang","middleName":"","lastName":"Wang","suffix":""},{"id":346561451,"identity":"f90aa3a0-a140-4057-9567-545b0e80d597","order_by":5,"name":"Ming-xian Chen","email":"","orcid":"","institution":"Xichang People's Hospital","correspondingAuthor":false,"prefix":"","firstName":"Ming-xian","middleName":"","lastName":"Chen","suffix":""},{"id":346561452,"identity":"fa9976bf-1184-4ac2-84c7-c51e0942154f","order_by":6,"name":"Hua Yang","email":"","orcid":"","institution":"Xichang People's Hospital","correspondingAuthor":false,"prefix":"","firstName":"Hua","middleName":"","lastName":"Yang","suffix":""},{"id":346561453,"identity":"f99d4d81-80ea-44f0-a14a-870eef32ce88","order_by":7,"name":"Hua-song Huang","email":"","orcid":"","institution":"Xichang People's Hospital","correspondingAuthor":false,"prefix":"","firstName":"Hua-song","middleName":"","lastName":"Huang","suffix":""},{"id":346561454,"identity":"eeb5199f-3900-4d1e-b61b-3a1b30fb3ace","order_by":8,"name":"Hou-chuan Chen","email":"","orcid":"","institution":"Xichang People's Hospital","correspondingAuthor":false,"prefix":"","firstName":"Hou-chuan","middleName":"","lastName":"Chen","suffix":""},{"id":346561455,"identity":"ffddd073-9f2c-412a-8b97-4224f1f76b24","order_by":9,"name":"Zhi-gang Chen","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAAzklEQVRIiWNgGAWjYBACefmDjY9/VPyXY2xvIFKL4Qzmw8YMZ5iNmXsOEGvNDbY0acY25kT2GQlE6mCc3WMmXXCGLYF35uONNxhqbKIJamGXOWNsPaOCJ09ydlqxBcOxtNwGgrY05Bje4DkjUWw4O8dMgrHhMGEtDAdyDCR42wwS9988Q6yWG2lJ0rxtCYmNM3iI1GLYc/iw4YwzB4wZe4B+SSDGL/LsjY0PPlQcAEbl4Y03PtTYEOEwJGAgkUCKcogWUnWMglEwCkbByAAAxfFEIW5Ap90AAAAASUVORK5CYII=","orcid":"","institution":"Xichang People's Hospital","correspondingAuthor":true,"prefix":"","firstName":"Zhi-gang","middleName":"","lastName":"Chen","suffix":""}],"badges":[],"createdAt":"2024-07-31 12:40:06","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-4835590/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-4835590/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":64384605,"identity":"f2e65f00-74bd-4231-84bf-6099c27a1e38","added_by":"auto","created_at":"2024-09-12 12:21:31","extension":"jpeg","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":113545,"visible":true,"origin":"","legend":"\u003cp\u003eLegend not included with this version\u003c/p\u003e","description":"","filename":"floatimage1.jpeg","url":"https://assets-eu.researchsquare.com/files/rs-4835590/v1/a8c4f4c8225b371c71d7e65e.jpeg"},{"id":64386731,"identity":"e9941184-5914-4f6e-98d3-909cd5e56a77","added_by":"auto","created_at":"2024-09-12 12:37:33","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":348459,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-4835590/v1/2e0194d2-9e05-404c-bc4b-5fe05d510e1f.pdf"}],"financialInterests":"No competing interests reported.","formattedTitle":"A rare young case of Embryonic rhabdomyosarcoma of the prostate with multiple metastases throughout the body: A case report","fulltext":[{"header":"Case Report","content":"\u003cp\u003eA 36-year-old man visited the outpatient clinic for one month due to dysuria, weak urine flow, and increased nocturia. He denied fever and other constitutional symptoms. He did not observe blood in urine and semen. No history of urinary tract infection, nephrolithiasis, malignancy or neurological disease was reported. The outpatient clinic arranged routine urine examinations and urinary tract color Doppler ultrasound examinations for patients. Due to the severe dysuria symptoms, the patient was treated with catheterization. The patient is admitted to the hospital on the advice of a doctor, after admission, a magnetic resonance imaging(MRI) scan of the pelvic cavity showed that the prostate was significantly enlarged(Prostate volume: 7.0*6.3*6.2cm), the shape of the prostate was irregular and its density was uneven (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003ea, b).\u003c/p\u003e \u003cp\u003eLaboratory analysis revealed white blood cell count 11.08 \u0026times; 10\u003csup\u003e9\u003c/sup\u003e/l, hemoglobin 12.8 g/dl, platelet count 257 \u0026times; 10\u003csup\u003e9\u003c/sup\u003e/l. Urinalysis, urine culture, electrolytes including fasting and post prandial blood sugar, serum calcium and alkaline phosphatase were unremarkable. Prostate specific antigen (tPSA) level was 0.45 ng/ml (normal PSA 0\u0026ndash;4 ng/ml) and free prostate specific antigen(fPSA) level was 0.03 ng/ml. A transrectal ultrasound guided biopsy of the prostate revealed prostate cancer. Due to the difficulty of pathological diagnosis, the patient\u0026rsquo;s pathological specimens were stained by immunohistochemistry. Immunohistochemistry confirmed the diagnosis of Embryonic rhabdomyosarcoma of the prostate (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003ec, d). Ki 67 index was elevated to 60%. Sections were negative for LCA, GATA-3, P63, CK-H, PSA, P504S, AR, CD30, SALL, CK, CD10, CyclinD1, NSE and S-100. Sections were positive for FLI-I, ERG, Syn, Myogenin, CD99, CD56, Vim and Des. The patient refused genetic testing. The patient underwent a PET-CT scan that showed multiple metastases throughout the patient's body.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e"},{"header":"Discussion","content":"\u003cp\u003eMen under 40 years of age reported in the literature on prostate cancer are very rare, with an incidence of 0.8\u0026ndash;1.1% [\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e]. The vast majority of prostate cancers are accompanied by elevated prostate-specific antigen (PSA) levels [\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e]. PSA level is lower in these patients due to poorly differentiated adenocarcinoma of prostate. So in poorly differentiated carcinoma, PSA level is not indicative of prostate cancer. Compared with elderly patients, men with early-onset prostate cancer are more likely to have more genetic variants, which is related to an increased risk of prostate cancer. In addition, most patients with early-onset prostate cancer are diagnosed as moderately-poorly differentiated diseases, so the management of patients with early-onset prostate cancer presents unique clinical challenges [\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e]. First-line therapy for prostate cancer includes androgen deprivation therapy (ADT), depriving both the normal and malignant prostate cells of androgens required for proliferation and survival. However, embryonic rhabdomyosarcoma is an androgen-independent tumor. Therefore, the treatment of this patient with ADT is ineffective. Embryonal rhabdomyosarcoma (ERMS) is a malignant soft tissue tumor with morphologic and immunophenotypic features of embryonic skeletal muscle [\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e]. The most common sites are cervical-cephalic and genitourinary and have worse prognosis [\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e]. Treatment options for embryonic rhabdomyosarcoma include chemotherapy, radiotherapy, Surgery, Immunotherapy [\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e]. The patient has tumor metastases in multiple organs throughout the body, and the curative effect of radical surgery on the patient\u0026rsquo;s prostate is also limited. For the patient, he should choose chemotherapy, radiotherapy and other treatment options.\u003c/p\u003e"},{"header":"Abbreviations","content":"\u003cdiv class=\"DefinitionList\"\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eRMS\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eRhabdomyosarcoma\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eMRI\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003emagnetic resonance imaging\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003efPSA\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003efree prostate specific antigen\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eADT\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eandrogen deprivation therapy\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eERMS\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eEmbryonal rhabdomyosarcoma\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003c/div\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eAcknowledgements\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNone.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthor\u0026nbsp;\u003c/strong\u003e\u003cstrong\u003eContributions\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eConception and design: KW and ZC. Acquisition of data: YO, ZZ, YJ, MC, HY, YH, ZS, HW, HH and HC. Manuscript editing: KW and FC. All authors contributed to the article and approved the submitted version.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFunding\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNONE\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eEthics approval and consent to participate\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eWritten informed consent to participate was obtained from the patient of this case report. A copy of the written consent is available for review by the Editor of this journal.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConsent for publication\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eWritten informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConflicts of Interest\u003c/strong\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eAll authors declare that there are no conflicts of interest.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eDate Availability Statement\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe raw data supporting the conclusions of this article will be made available by the authors without undue reservation. Please contact the author Kai Wang (email: [email protected]).\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\u003cli\u003e\u003cspan\u003eCulp MaryBeth B, Soerjomataram Isabelle, Efstathiou Jason A, et al. Recent Global Patterns in Prostate Cancer Incidence and Mortality Rates. [J] Eur Urol. 2020;77:38\u0026ndash;52.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGilles DJ-PA, Silke G, et al. Management of Prostate Cancer in Elderly Patients: Recommendations of a Task Force of the International Society of Geriatric Oncology. [J] Eur Urol. 2017;72:521\u0026ndash;31.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDrummond CJ, Hanna JA, Garcia MR, et al. Hedgehog Pathway Drives Fusion-Negative Rhabdomyosarcoma Initiated From Non-myogenic Endothelial Progenitors. Cancer Cell. 2018;33:108\u0026ndash;24. e5.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePastore G, Peris-Bonet R, Carli M, et al. Childhood soft tissue sarcomas incidence and survival in European children (1978\u0026ndash;1997): report from the Automated Childhood Cancer Information System project. Eur J Cancer. 2006;42:2136\u0026ndash;49.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWeiss SW, Goldblum J, Weiss SW, et al. editors. Enzinger and Weiss\u0026rsquo;s Soft Tissue Tumors. 4th ed. St. Louis: CV Mosby; 2001. pp. 785\u0026ndash;835.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRoberts JT, Essenhigh DM. Adenocarcinoma of prostate in 40-year-old body-builder. [J] Lancet. 1986;2:742.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRuska KM, Partin AW, Epstein JI, et al. Adenocarcinoma of the prostate in men younger than 40 years of age: diagnosis and treatment with emphasis on radical prostatectomy findings. [J] Urol. 1999;53:1179\u0026ndash;83.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCazanave Mora Juliette M et al. Del Valle Garc\u0026iacute;a Ruben, P\u0026eacute;rez L\u0026oacute;pez Lilian. Measurement of total and free prostate specific antigen (PSA) in human serum samples using an ultra-microanalytical system.[J].J Pharm Biomed Anal, 2021, 208: 114470.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLange EM, Salinas CA, Zuhlke KA, Ray AM, Wang Y, Lu Y, Ho LA, Luo J, Cooney KA. Early onset prostate cancer has a significant genetic component. Prostate. 2012;72:147\u0026ndash;56.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eManiraj J, Ann MR, Munchel Ashley Taylor-King. Embryonal Rhabdomyosarcoma with Posttherapy Cytodifferentiation and Aggressive Clinical Course. [J]. Case Rep Pathol, 2021, 2021: 1800854.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePappo AS, Shapiro DN, Crist WM, et al. Biology and therapy of pediatric rhabdomyosarcoma. [J]. J Clin Oncol. 1995;13:2123\u0026ndash;39.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLeaphart Cynthia,Rodeberg David,Pediatric surgical oncology: management of rhabdomyosarcoma[. J] Surg Oncol, 2007, 16: 173\u0026ndash;85.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCatalina R-M, Goldberg John M, Coronado Munoz Alvaro J, et al. Rhabdomyosarcoma in adults: new perspectives on therapy. [J]. Curr Treat Options Oncol. 2015;16:27.\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"Embryonic rhabdomyosarcoma, Prostate, Urology","lastPublishedDoi":"10.21203/rs.3.rs-4835590/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-4835590/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003eProstate cancer is the second most commonly diagnosed cancer and the sixth leading cause of cancer death among men worldwide, with an estimated 1 276 000 new cancer cases and 359 000 deaths in 2018[\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e]. The median age at diagnosis is 66\u0026nbsp;year, and 69% of deaths occur in men aged 75 yr[\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e]. As the morbidity and mortality rates rise sharply with age, the burden of prostate cancer will increase with the exponential aging of the population. The pathological type of prostate cancer is mainly adenocarcinoma (98.1%), and other types are relatively rare. Other pathological types of prostate cancer include iprostate duct (endometrioid) ademocarcinoma, small cell carcinoma, smucinous adenocarcinoma, signet ring cell carcinoma, transitional cell carcinoma, Sarcomatoid carcinoma, squamous cell carcinoma, lymphoepithelioid carcinoma, adenoid cystic carcinoma, etc. Rhabdomyosarcoma (RMS) is a soft tissue sarcoma that histologically resembles embryonic skeletal muscle. It can occur anywhere in the body, including tissues devoid of skeletal muscles. The cell of origin of RMS remains unknown, however, recent evidence suggests that RMS can originate from aberrant development of non-myogenic cells [\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e]. Rhabdomyosarcoma is a common malignant tumor in children. In fact, it accounts for more than 50% of all soft tissue sarcomas in children [\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e]. However, rhabdomyosarcoma is a rare adult malignant tumor, and it accounts for only 3% of all soft tissue sarcomas [\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e]. Rhabdomyosarcoma is very rare in prostate tumors.\u003c/p\u003e","manuscriptTitle":"A rare young case of Embryonic rhabdomyosarcoma of the prostate with multiple metastases throughout the body: A case report","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2024-09-12 12:21:26","doi":"10.21203/rs.3.rs-4835590/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"600c7bcd-1ce9-40a7-bd98-53cd301f2257","owner":[],"postedDate":"September 12th, 2024","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[],"tags":[],"updatedAt":"2024-09-12T12:21:28+00:00","versionOfRecord":[],"versionCreatedAt":"2024-09-12 12:21:26","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-4835590","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-4835590","identity":"rs-4835590","version":["v1"]},"buildId":"qtupq5eGEP_6zYnWcrvyt","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}